CoChat

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index, and 1 are not checked yet.

Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study

Open access

Abstract

BACKGROUND: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are considered to have similar renoprotective effects; so far there has been no consensus about their priorities. This study aimed to compare ACEIs and ARBs for major renal outcomes and survival in a 15-year cohort of adults with diabetes. METHODS: This study utilized Taiwan's medical and pharmacy claims data in the Longitudinal Cohort of Diabetes Patients. The primary outcome was long-term dialysis, and secondary outcomes were hospitalization for acute kidney injury, hospitalization for hyperkalemia, all-cause death, cardiovascular death, and non-cardiovascular death. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes comparing ACEIs with ARBs. We conducted subgroup analyses and interaction tests among patients with different age and comorbid diseases. RESULTS: A total of 34,043 patients received ACEIs and 23,772 patients received ARBs. No differences were found for primary or secondary outcomes in the main analyses. ACEIs showed significantly lower hazard than ARBs for long-term dialysis among patients with cardiovascular disease (HR 0.80, 95% CI 0.66-0.97, interaction P = 0.003) or chronic kidney disease (0.81, 0.71-0.93, interaction P = 0.001). CONCLUSIONS: Our analyses show similar effects of ACEIs and ARBs in patients with diabetes. However, ACEIs might provide additional renoprotective effects among patients who have cardiovascular disease or chronic kidney disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0177654

Cites

42 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Summary of patient selection. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
Fig 1 Summary of patient selection. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.CC BY · PubMed Central
Fig 2 Kaplan-Meier cumulative incidence of time to event for long-term dialysis, acute kidney injury, hyperkalemia, all-cause death, cardiovascular death, and non-cardiovascular death in patients treated with ACEI or ARB. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
Fig 2 Kaplan-Meier cumulative incidence of time to event for long-term dialysis, acute kidney injury, hyperkalemia, all-cause death, cardiovascular death, and non-cardiovascular death in patients treated with ACEI or ARB. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.CC BY · PubMed Central
Fig 3 Hazard ratios and 95% confidence intervals comparing ACEI therapy with ARB therapy for study outcomes of (A) Long-term dialysis; (B) Acute kidney injury; (C) Hyperkalemia; (D) All-cause death; (E) Cardiovascular death; and (F) Non-cardiovascular death. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
Fig 3 Hazard ratios and 95% confidence intervals comparing ACEI therapy with ARB therapy for study outcomes of (A) Long-term dialysis; (B) Acute kidney injury; (C) Hyperkalemia; (D) All-cause death; (E) Cardiovascular death; and (F) Non-cardiovascular death. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 33

Metadata

Authors
Wu, H.-Y., Peng, C.-L., Chen, P.-C., Chiang, C.-K., Chang, C.-J., Huang, J.-W., Peng, Y.-S., Tu, Y.-K., Chu, T.-S., Hung, K.-Y., & Chien, K.-L.
Affiliations
  • National Taiwan University (TW)
  • Chang Gung University (TW)
Corresponding author
  • Hung, Kuan-Yu
  • Chien, Kuo-Liong
Venue
PLOS ONE
Published
2017-05-15
Volume
12
Issue
5
Pages
e0177654
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2614138413
Cited by
33
References
42
Citations by year
2025: 8 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 1
FWCI
2.93
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Ministry of Science and Technology, Taiwan (MOST 103-2314-B-418-003-MY2)
  • National Health Research Institutes (NHRI-EX105-10510PC, NHRI-EX106-10510PC)
  • Far Eastern Memorial Hospital (FEMH-EX105-10510PC, FEMH-EX106-10510PC)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
ACE inhibitors, angiotensin receptor blockers, diabetes mellitus, renal protection, chronic dialysis, acute kidney injury, hyperkalemia, cardiovascular mortality, all-cause mortality, chronic kidney disease, cardiovascular disease, comparative effectiveness
MeSH terms
Adult, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Combined Modality Therapy, Diabetes Mellitus, Diabetic Nephropathies, Female, Humans, Kidney, Male, Middle Aged, Population Surveillance, Taiwan, Cohort Studies, Comorbidity, Proportional Hazards Models, Treatment Outcome, Renal Insufficiency, Chronic, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study. https://app.cochat.ai/papers/10.1371/journal.pone.0177654
The paper
Wu, H.-Y., Peng, C.-L., Chen, P.-C., Chiang, C.-K., Chang, C.-J., Huang, J.-W., Peng, Y.-S., Tu, Y.-K., Chu, T.-S., Hung, K.-Y., & Chien, K.-L. (2017). Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0177654

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.